Roche's Genentech wins first FDA approval for primary membranous nephropathy treatment with Gazyva
Genentech's Gazyva became the first FDA-approved treatment for adults with primary membranous nephropathy at risk of progression. In a Phase III trial, 36.1% of patients receiving Gazyva achieved complete proteinuria remission at two years, versus 5.7% receiving tacrolimus.
1. FDA approval
Roche unit Genentech's Gazyva became the first FDA-approved treatment for adults with primary membranous nephropathy at risk of disease progression. In the Phase III MAJESTY trial, complete proteinuria remission at two years was reported in 36.1% of patients receiving Gazyva and 5.7% receiving tacrolimus (p<0.001). The decision is Gazyva's third FDA approval in immune-mediated kidney diseases, following approvals for idiopathic nephrotic syndrome and lupus nephritis.





